Hepatitis C virus (HCV) infection remains one of the main causes of chronic liver disease worldwide. The advent of direct-acting antivirals (DAAs) has significantly improved the course of patients with chronic HCV infection (CHC), due to the ability of these drugs to achieve high rates of sustained virological response (SVR). These exceedingly high rates of SVR and the excellent safety data have been confirmed in real life practice. Evolving guidelines have been issued by national and international scientific societies in accordance with the progression of clinical knowledge and the availability of new DAAs. These recommendations, however, may not be applied universally because of delays in drugs reimbursability in different countries and because some National Health Systems identify only patients with advanced disease as a treatment priority. Italy in this regard is a prototype about DAAs treatment of CHC patients. With the aim to assess the Italian treatment experience with DAAs and to respond to unmet needs in treatment optimization of antiviral therapy in specific settings of CHC patients, a group of Italian experts met in Stresa in February 2017. The summary of the considerations arising from this two-day meeting and some statements regarding a few open issues are reported in this position paper.

Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel / Viganò, Mauro; Perno, Carlo Federico; Craxì, Antonio; Aghemo, Alessio; Alberti, Alfredo; Andreone, Pietro; Andreoni, Massimo; Bonora, Stefano; Brunetto, Maurizia Rossana; Bruno, Raffaele; Bruno, Savino; Calvaruso, Vincenza; Caporaso, Nicola; Ceccherini-Silberstein, Francesca; Cento, Valeria; Ciancio, Alessia; Colombatto, Piero; Degasperi, Elisabetta; Di Marco, Vito; Di Perri, Giovanni; D'offizi, Gianpiero; Fagiuoli, Stefano; Ferrari, Carlo; Gaeta, Giovanni Battista; Pellicelli, Adriano; Petta, Salvatore; Piovesan, Sara; Puoti, Massimo; Raimondo, Giovanni; Russo, Francesco Paolo; Taliani, Gloria; Trama, Ugo; Villa, Erica; Zignego, Anna Linda. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - 49:7(2017), pp. 731-741. [10.1016/j.dld.2017.03.027]

Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel

Andreone, Pietro;Bruno, Raffaele;Bruno, Savino;DI MARCO, VITO;Ferrari, Carlo;Taliani, Gloria;Villa, Erica;
2017

Abstract

Hepatitis C virus (HCV) infection remains one of the main causes of chronic liver disease worldwide. The advent of direct-acting antivirals (DAAs) has significantly improved the course of patients with chronic HCV infection (CHC), due to the ability of these drugs to achieve high rates of sustained virological response (SVR). These exceedingly high rates of SVR and the excellent safety data have been confirmed in real life practice. Evolving guidelines have been issued by national and international scientific societies in accordance with the progression of clinical knowledge and the availability of new DAAs. These recommendations, however, may not be applied universally because of delays in drugs reimbursability in different countries and because some National Health Systems identify only patients with advanced disease as a treatment priority. Italy in this regard is a prototype about DAAs treatment of CHC patients. With the aim to assess the Italian treatment experience with DAAs and to respond to unmet needs in treatment optimization of antiviral therapy in specific settings of CHC patients, a group of Italian experts met in Stresa in February 2017. The summary of the considerations arising from this two-day meeting and some statements regarding a few open issues are reported in this position paper.
12-apr-2017
49
7
731
741
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel / Viganò, Mauro; Perno, Carlo Federico; Craxì, Antonio; Aghemo, Alessio; Alberti, Alfredo; Andreone, Pietro; Andreoni, Massimo; Bonora, Stefano; Brunetto, Maurizia Rossana; Bruno, Raffaele; Bruno, Savino; Calvaruso, Vincenza; Caporaso, Nicola; Ceccherini-Silberstein, Francesca; Cento, Valeria; Ciancio, Alessia; Colombatto, Piero; Degasperi, Elisabetta; Di Marco, Vito; Di Perri, Giovanni; D'offizi, Gianpiero; Fagiuoli, Stefano; Ferrari, Carlo; Gaeta, Giovanni Battista; Pellicelli, Adriano; Petta, Salvatore; Piovesan, Sara; Puoti, Massimo; Raimondo, Giovanni; Russo, Francesco Paolo; Taliani, Gloria; Trama, Ugo; Villa, Erica; Zignego, Anna Linda. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - 49:7(2017), pp. 731-741. [10.1016/j.dld.2017.03.027]
Viganò, Mauro; Perno, Carlo Federico; Craxì, Antonio; Aghemo, Alessio; Alberti, Alfredo; Andreone, Pietro; Andreoni, Massimo; Bonora, Stefano; Brunetto, Maurizia Rossana; Bruno, Raffaele; Bruno, Savino; Calvaruso, Vincenza; Caporaso, Nicola; Ceccherini-Silberstein, Francesca; Cento, Valeria; Ciancio, Alessia; Colombatto, Piero; Degasperi, Elisabetta; Di Marco, Vito; Di Perri, Giovanni; D'offizi, Gianpiero; Fagiuoli, Stefano; Ferrari, Carlo; Gaeta, Giovanni Battista; Pellicelli, Adriano; Petta, Salvatore; Piovesan, Sara; Puoti, Massimo; Raimondo, Giovanni; Russo, Francesco Paolo; Taliani, Gloria; Trama, Ugo; Villa, Erica; Zignego, Anna Linda
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1590865817308071-main.pdf

accesso aperto

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 813.58 kB
Formato Adobe PDF
813.58 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1154216
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 12
social impact